The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Hepatitis B Virus (HBV) Market During The Forecast Period?
The hepatitis b virus (hbv) market size has shown substantial growth over recent years. It is projected to expand from $7.31 billion in 2025 to $7.98 billion in 2026, at a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be linked to factors such as the high prevalence of hbv in Asia-Pacific, insufficient awareness concerning hbv treatment, low vaccination coverage during initial years, a reliance on generic antiviral drugs, and an increasing incidence of chronic liver disease.
The market size for the hepatitis B virus (HBV) is projected to experience substantial growth over the next few years. It is expected to reach $11.77 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. The anticipated expansion during this forecast period stems from increased research and development in HBV treatments, the broadening of government vaccination initiatives, the adoption of precision medicine, escalating healthcare expenditure, and improvements in screening and diagnostic infrastructure. Key trends anticipated in the forecast period include the growing acceptance of antiviral therapies, the rise of hepatitis B vaccination programs, the creation of combination therapies, a focus on managing HBV in pediatric and geriatric populations, and the wider availability of screening and diagnostic services.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12867&type=smp
What Major Factors Are Driving The Hepatitis B Virus (HBV) Market Forward?
The widespread occurrence of hepatitis B infection is anticipated to drive the expansion of the hepatitis B virus market in the coming years. Hepatitis B, a liver ailment caused by the hepatitis B virus (HBV), can be prevented via vaccination. An escalation in hepatitis B infection rates is poised to elevate the demand for diagnostic tests and treatment solutions. For example, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focused on the control and prevention of disease, injury, and disability, estimated 13,300 new hepatitis B infections and 69,800 new hepatitis C infections in 2023. Therefore, the significant prevalence of hepatitis B infection will propel the hepatitis B virus market.
What Segment Categories Shape The Hepatitis B Virus (HBV) Market Segment Landscape?
The hepatitis b virus (hbv) market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery
3) By Age Group: Pediatrics, Adults, Seniors
4) By End User: Medical Providers, Patients, Healthcare Payers
Subsegments:
1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV
2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
What Market Trends Are Affecting The Hepatitis B Virus (HBV) Market?
Major companies operating in the HBV market are prioritizing the advancement of innovative therapies through ongoing clinical trials and expediting regulatory pathways to enhance treatment efficacy and secure a competitive advantage. For instance, in August 2025, Aligos Therapeutics, a US-based therapeutics company, initiated patient dosing in its Phase II B-SUPREME trial, which is evaluating ALG-000184, a pioneering oral capsid assembly modulator for chronic hepatitis B. This randomized, double-blind study plans to enroll approximately 200 treatment-naïve adults, comparing ALG-000184 with tenofovir disoproxil fumarate over 48 weeks. The primary objective is to achieve HBV DNA levels below quantifiable limits in both HBeAg-positive and HBeAg-negative participants, with secondary endpoints evaluating safety, pharmacokinetics, and antigen changes. Earlier Phase I data indicated strong antiviral activity and good tolerability, thereby supporting the drug’s potential. Interim results are anticipated in 2026, and the full topline findings are expected in 2027.
Who Are The Companies Operating Across The Hepatitis B Virus (HBV) Market Value Chain?
Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc.
Get The Full Hepatitis B Virus (HBV) Market Report:
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Which Region Accounts For The Largest Portion Of The Hepatitis B Virus (HBV) Market?
North America was the largest region in the hepatitis B Virus (HBV) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis b virus (hbv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hepatitis B Virus (HBV) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Market 2026, By The Business Research Company
Hepatitis B Virus Hbv Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Chronic Hepatitis B Market Report 2026
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Preventive Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model